A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis

Ruxolitinib (RUX) is extensively used in myelofibrosis (MF). Despite its early efficacy, most patients lose response over time and, after discontinuation, have a worse overall survival (OS). Currently, response criteria able to predict OS in RUX-treated patients are lacking, leading to uncertainty r...

Descripción completa

Detalles Bibliográficos
Autores principales: Maffioli, Margherita, Mora, Barbara, Ball, Somedeb, Iurlo, Alessandra, Elli, Elena Maria, Finazzi, Maria Chiara, Polverelli, Nicola, Rumi, Elisa, Caramella, Marianna, Carraro, Maria Cristina, D’Adda, Mariella, Molteni, Alfredo, Sissa, Cinzia, Lunghi, Francesca, Vismara, Alessandro, Ubezio, Marta, Guidetti, Anna, Caberlon, Sabrina, Anghilieri, Michela, Komrokji, Rami, Cattaneo, Daniele, Della Porta, Matteo Giovanni, Giorgino, Toni, Bertù, Lorenza, Brociner, Marco, Kuykendall, Andrew, Passamonti, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941454/
https://www.ncbi.nlm.nih.gov/pubmed/35130339
http://dx.doi.org/10.1182/bloodadvances.2021006889

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941454/
https://www.ncbi.nlm.nih.gov/pubmed/35130339
http://dx.doi.org/10.1182/bloodadvances.2021006889

Ejemplares similares